ATS 2019 Virtual Final Program

CLINICAL POSTER DISCUSSION SESSION C101 NON-IDIOPATHIC INTERSTITIAL PNEUMONIA NATURAL HISTORY AND PROGNOSIS AND ILD THERAPY 2:15 p.m. - 4:15 p.m. KBHCCD Room C140/C142 (Level 1) Poster Viewing 2:15-3:00 Discussion 3:00-4:15 Chairing: L. Richeldi, MD, PhD, Rome, Italy M. Porteous, MD, Philadelphia, PA E.A. Renzoni, PhD, London, United Kingdom 101 Evaluation of the Natural History of Sarcoidosis in a Population-Based Cohort/ J. Simmering, P.M. Polgreen, J.L. Kuntz, A. Gerke, Iowa City, IA, p.A5608 102 Role of Baseline Dyspnea Index (BDI) and Transition Dyspnea Index (TDI) as a Measure of Self-Reported Health Related Quality of Life in Sarcoidosis Patients/ O.N. Obi, M.A. Judson, L.A. Maier, A.U. Wells, R.P. Baughman, Greenville, NC, p.A5609 103 Epidemiology and Healthcare Utilization of Spontaneous Pneumothorax and Diffuse Cystic Lung Diseases in the United States/ A.M. Cattran, N. Gupta, K. Meganathan, Cincinnati, OH, p.A5610 104 The Value of High Resolution Computed Tomography and Surgical Lung Biopsy in Predicting Outcome for Patients with Fibrotic Hypersensitivity Pneumonia/ K.T. Hughes, Ann Arbor, MI, p.A5611 105 Targeted High-Resolution CT Re-Scan in Patients with Lymphangioleiomyomatosis Lead to Higher Cyst Score Accuracy/ T. Larsen, A. Hasani, S. Rollison, T. Machado, A. Jones, P. Julien-Williams, M. Chen, H. Wen, J. Moss, Bethesda, MD, p.A5612 106 Survival of Patients with Acute Exacerbations of Rheumatoid Arthritis Associated Interstitial Lung Disease/ S. Blumhof, M. Danila, D. Sun, V.G. Valentine, T. Luckhardt, J.A. De Andrade, S.L. Bridges, S.R. Duncan, Birmingham, AL, p.A5613 107 Feasibility and Efficacy of Cohort Enrichment for Progressive Lung Fibrosis in Systemic Sclerosis - a EUSTAR Database Analysis/ A.-M. Hoffmann-Vold, M. Gahlemann, N. Graf, P. Airò, L.P. Ananyeva, L. Czirják, S. Guiducci, E. Hachulla, M. Li, C. Mihai, G. Riemekasten, P. Sfikakis, G. Valentini, O. Kowal-Bielecka, Y. Allanore, O. Distler, Oslo, Norway, p.A5614 108 Prediction and Frequency of Progressive Lung Fibrosis in Patients with Systemic Sclerosis-Associated Interstitial Lung Disease in the World’s Largest Database of Patients with Systemic Sclerosis (EUSTAR)/ A.-M. Hoffmann-Vold, Y. Allanore, M. Alves, N. Graf, P. Airò, L.P. Ananyeva, L. Czirják, S. Guiducci, E. Hachulla, M. Li, C. Mihai, G. Riemekasten, P. Sfikakis, G. Valentini, O. Kowal-Bielecka, O. Distler, Oslo, Norway, p.A5615 109 Lung Transplantation for Lymphangioleiomyomatosis: A Review of the United Network for Organ Sharing Database/ M.U. Khawar, D. Yazdani, Z. Zhu, R. Jandarov, N. Gupta, Cincinnati, OH, p.A5616 110 Pathologic Findings in End-Stage Sarcoidosis: A Quantitative Morphometric Evaluation/ S. Hurley, D.A. Culver, X. Wang, X. Han, M.M. Budev, C.F. Farver, Cleveland, OH, p.A5617 111 Is “End-Stage” Sarcoidosis Really “End-Stage”? Clinical and Pathologic Correlations of 35 Explants/ S. Hurley, C.F. Farver, X. Wang, X. Han, M.M. Budev, D.A. Culver, Cleveland, OH, p.A5618 112 Advanced Care Planning (ACP) Model in Idiopathic Pulmonary Fibrosis/ A. Daoud, J. Richman-Eisenstat, M. Kalluri, Edmonton, Canada, p.A5619 113 Antifibrotic Therapy Associated Changes in Lung Function in a Community-Based Idiopathic Pulmonary Fibrosis Cohort/ D. Zhu, B. Cantrill, K. Biblowitz, P.A. Chung, R. Vij, M.E. Strek, S.K. Bellam, A.O. Adegunsoye, Evanston, IL, p.A5620 114 Recurrent Acute Exacerbations of Fibrotic Interstitial Lung Diseases/ A. Suzuki, Y. Kondoh, K.K. Brown, T. Kimura, K. Kataoka, T. Matsuda, T. Yokoyama, M. Ando, N. Hashimoto, K. Sakamoto, Y. Hasegawa, Nagoya, Japan, p.A5621 115 Treatment Patterns in Patients with Idiopathic Pulmonary Fibrosis (IPF): Data from the IPF-PRO Registry/ M.L. Salisbury, C.S. Conoscenti, D.A. Culver, E. Yow, M. Neely, S. Bender, N. Hartmann, S. Palmer, T. Leonard, Ann Arbor, MI, p.A5622 116 Clinical Development of OATD-01 - a Novel, Chitinase Inhibitor for Treatment of Interstitial Lung Diseases/ R. Dyjas, J. Lipner, B. Dymek, M. Mlacki, A. Zagozdzon, A. Lipinska, M. Paplinska-Goryca, P. Nejman-Gryz, M. Proboszcz, M. Maskey-Warzechowska, K. Gorska, N. Przysucha, R. Krenke, P. Dobrzanski, K. Dzwonek, S. Pikul, Warsaw, Poland, p.A5623 117 Disparities in the Treatment of Patients with Interstitial Lung Disease in Canada/ D. Assayag, K. Garlick, K.A.M. Johannson, C.D. Fell, M.R.J. Kolb, G.P. Cox, N. Hambly, H. Manganas, J. Morisset, J.H. Fisher, S. Shapera, M. Sadatsafavi, P. Wilcox, A.J. Halayko, N. Khalil, C.J. Ryerson, Montreal, Canada, p.A5624 118 Consistent Effect of Nintedanib in Patients with IPF and Degrees of Impairment in Gas Exchange/ L. Richeldi, M. Kolb, S. Jouneau, W.A. Wuyts, I. Tschoepe, S. Stowasser, M. Quaresma, G. Raghu, Rome, Italy, p.A5625 119 Machine Learning Models for Predicting Mortality in Idiopathic Pulmonary Fibrosis (IPF) Patients/ Z. Zhu, J. Geng, S. Menjoge, S. Stowasser, S. Lu, W. Tang, Ridgefield, CT, p.A5626 120 Characteristics of Patients with Progressive Fibrosing Interstitial Lung Diseases (ILDs) in the INBUILD Trial of Nintedanib/ K.R. Flaherty, A.U. Wells, E. Clerisme-Beaty, V. Cottin, A. Devaraj, Y. Inoue, L. Richeldi, S. Walsh, R.-G. Goeldner, R. Schlenker-Herceg, K.K. Brown, Ann Arbor, MI, p.A5627 121 Clinical Phenotypes Using Cluster Analyses Predicts Homogeneous Outcomes in the Pulmonary Fibrosis Foundation Registry/ A.O. Adegunsoye, E. Freiheit, M.E. Strek, Chicago, IL, p.A5628 ATS 2019 • Dallas, TX 300 TUESDAY • MAY 21